MAIN CONTENT
Novartis makes a major bet on Abogen’s mRNA platform
Abogen Biosciences says Novartis has entered a licensing and option agreement covering its RNA platform. The centerpiece is ABO2203, an mRNA-encoded CD19xCD3 T-cell engager designed to direct the body to produce proteins that recruit T cells against disease-driving B cells in autoimmune conditions. Novartis will pay $575 million upfront, while development, regulatory and commercial milestones could add roughly $7.2 billion.
The structure gives Novartis access to a new therapeutic approach without acquiring Abogen outright. The Swiss company also receives exclusive options to license additional programs built on Abogen’s proprietary RNA platform. Such arrangements are increasingly attractive because large drugmakers can stage their risk over time, while Chinese biotechs receive capital to fund domestic research and retain strategic flexibility.
Licensing has become the main bridge between China and global drugmakers
Novo Nordisk has also signed with Hengrui Pharma for HRS-1596 outside mainland China, Hong Kong, Macao and Taiwan. The candidate is a once-weekly oral dual GLP-1/GIP receptor agonist.

















